Avalyn Pharma (AVLN)
Develops inhaled pirfenidone and nintedanib candidates for pulmonary fibrosis.
$36.02
Pre-market+0.55 (+1.55%)
At close$35.47(+0.54%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| Cost of revenue | 0 | 0 |
| Gross profit | 0 | 0 |
| 28 | 31 | |
| Research & development | 23 | 25 |
| 5 | 6 | |
| General & administrative | 5 | 0 |
| Operating income | −28 | −31 |
| 1 | 2 | |
| Interest income | 1 | 3 |
| Interest expense | 0 | 0 |
| Other non-operating income | −1 | 0 |
| Income before tax | −27 | −29 |
| Net income from continuing operations | −27 | −29 |
| Net income | −27 | −29 |
| EPS, basic | −$0.64 | −$0.65 |
| EPS, diluted | −$0.64 | −$0.65 |
| Weighted average shares, basic | 42 | 44 |
| Weighted average shares, diluted | 42 | 44 |
| EBITDA | −27 | −31 |
| Depreciation & amortization | 0 | 0 |
| EBIT | −27 | −31 |